M. P. Glauser

15.8k total citations · 5 hit papers
155 papers, 11.7k citations indexed

About

M. P. Glauser is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, M. P. Glauser has authored 155 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Epidemiology, 62 papers in Infectious Diseases and 37 papers in Immunology. Recurrent topics in M. P. Glauser's work include Antibiotics Pharmacokinetics and Efficacy (35 papers), Antimicrobial Resistance in Staphylococcus (33 papers) and Infective Endocarditis Diagnosis and Management (29 papers). M. P. Glauser is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (35 papers), Antimicrobial Resistance in Staphylococcus (33 papers) and Infective Endocarditis Diagnosis and Management (29 papers). M. P. Glauser collaborates with scholars based in Switzerland, United States and Belgium. M. P. Glauser's co-authors include Thierry Calandra, Didier Heumann, Jacques Billé, J. D. Baumgartner, P Francioli, Philippe Moreillon, Gláucia Zanetti, Abraham I. Braude, Claudio Viscoli and Thierry Roger and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

M. P. Glauser

154 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coli

1982 779 citations M. P. Glauser et al. profile →
Protection from septic shock by neutralization of macrophage migration inhibitory factor

2000 616 citations Thierry Calandra, Didier Le Roy et al. profile →
Septic shock: pathogenesis

1991 593 citations M. P. Glauser, J. D. Baumgartner et al. profile →
CD14 Is a pattern recognition receptor

1994 586 citations Didier Heumann, M. P. Glauser et al. profile →
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors

1999 498 citations M. P. Glauser et al. profile →

Peers

Countries citing papers authored by M. P. Glauser

Since Specialization

Citations

This map shows the geographic impact of M. P. Glauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. P. Glauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. P. Glauser more than expected).

Fields of papers citing papers by M. P. Glauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. P. Glauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. P. Glauser. The network helps show where M. P. Glauser may publish in the future.

Co-authorship network of co-authors of M. P. Glauser

This figure shows the co-authorship network connecting the top 25 collaborators of M. P. Glauser. A scholar is included among the top collaborators of M. P. Glauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. P. Glauser. M. P. Glauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patients 2006 ·Clinical Microbiology and Infection ·Claudio Viscoli, Alain Cometta, Winfried V. Kern, R. De Bock, M Paesmans, F. Crokaert, M. P. Glauser, Thierry Calandra	56
2	Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive Aspergillosis 2003 ·Clinical Infectious Diseases ·John E. Bennett, John H. Powers, Ben de Pauw, William E. Dismukes, John N. Galgiani, M. P. Glauser, Raoul Herbrecht, Carol A. Kauffman, Jeannette Y. Lee, Peter G. Pappas, John Rex, Paul E. Verweij, Claudio Viscoli, Thomas J. Walsh	7
3	Forum Report: Issues in the Evaluation of Diagnostic Tests, Use of Historical Controls, and Merits of the Current Multicenter Collaborative Groups 2003 ·Clinical Infectious Diseases ·John E. Bennett, Carol A. Kauffman, Thomas J. Walsh, Ben de Pauw, William E. Dismukes, John N. Galgiani, M. P. Glauser, Raoul Herbrecht, Jeannette Y. Lee, Peter G. Pappas, John H. Powers, John Rex, Paul E. Verweij, Claudio Viscoli	8
4	Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients 2002 ·Clinical Microbiology and Infection ·M. P. Glauser, U. Brennscheidt, Oliver A. Cornely, Andrew Grigg, Á Figuera, Constance Keyserling, (unknown), Larry W. Welling, Kenneth J. Tack	5
5	Critical Role of Lipopolysaccharide-Binding Protein and CD14 in Immune Responses against Gram-Negative Bacteria 2001 ·The Journal of Immunology ·Didier Le Roy, Franco Di Padova, Yoshiyuki Adachi, M. P. Glauser, Thierry Calandra, Didier Heumann	75
6	Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation 2000 ·Critical Care Medicine ·Edward Abraham, Michael A. Matthay, Charles A. Dinarello, Jean‐Louis Vincent, Jonathan Cohen, Steven M. Opal, M. P. Glauser, Polly E. Parsons, Charles J. Fisher, John E. Repine	263
7	Pathophysiologic basis of sepsis: Considerations for future strategies of intervention 2000 ·Critical Care Medicine ·M. P. Glauser	78
8	Neutropenia: clinical implications and modulation 2000 ·Intensive Care Medicine ·M. P. Glauser	6
9	Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci 1999 ·Journal of Antimicrobial Chemotherapy ·José M. Entenza, Isabelle Caldelari, M. P. Glauser, Philippe Moreillon	16
10	Empiric Therapy of Bacterial Infections in Patients with Severe Neutropenia 1998 ·Diagnostic Microbiology and Infectious Disease ·M. P. Glauser	18
11	Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations 1997 ·Critical Care Medicine ·(unknown), (unknown), Sally Betz Corradin, René Chiolero, Bertrand Yersin, Harald Gallati, M. Assicot, Claude Bohuon, Jean-Daniel Baumgartner, M. P. Glauser, Didier Heumann	304
12	The Inflammatory Cytokines 1996 ·Drugs ·M. P. Glauser	110
13	Increased Circulating Soluble Cd14 Is Associated With High Mortality In Gram-Negative Septic Shock 1995 ·The Journal of Infectious Diseases ·R. Landmann, W. Zimmerli, Sebastiano Sansano, Susanne Link, Andreas Hahn, M. P. Glauser, Thierry Calandra	184
14	Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma 1994 ·Journal of Immunological Methods ·Didier Heumann, Philippe Gallay, Didier Le Roy, (unknown), M. P. Glauser	7
15	Role of Amoxicillin Serum Levels for Successful Prophylaxis of Experimental Endocarditis Due to Tolerant Streptococci 1994 ·The Journal of Infectious Diseases ·Ursula Flückiger, P Francioli, J. Blaser, M. P. Glauser, Philippe Moreillon	35
16	Task Force: Guidelines for the problem of sepsis (ESICM) 1994 ·Intensive Care Medicine ·Jean‐Louis Vincent, L. G. Thijs, Konrad Reinhart, Jan A. Hazelzet, Christian Brun‐Buisson, Jean Carlet, Jean‐Roger Le Gall, Peter M. Suter, Jukka Takala, Jonathan Cohen, John D. Edwards, M. P. Glauser, Antonino Gullo, M. Hemmer, (unknown), Matthias Langer, Jordi Rello, H.-P. Schuster, David Bihari, (unknown)	21
17	Correlation between in vitro susceptibility ofCandida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients 1993 ·European Journal of Clinical Microbiology & Infectious Diseases ·Nicolas Troillet, Christian Durussel, Jacques Billé, M. P. Glauser, J. P. Chave	90
18	Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group. 1992 ·IRIS ·Éric Girardin, J. D. Baumgartner, François Beaufils, F. Leclerc, Georges E. Grau, S. Suter, M. P. Glauser	60
19	Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. 1990 ·The Journal of Experimental Medicine ·J. D. Baumgartner, Didier Heumann, J. Gérain, P. Weinbreck, Georges E. Grau, M. P. Glauser	122
20	The inflammatory response and tissue damage 1987 ·Pediatric Nephrology ·M. P. Glauser, Pascal Meylan, Jacques Billé	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact